ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

1:00PM-2:30PM: Abstract Number: 2552

Changes in Social Determinants of Health Needs Uncovered by a Rheumatology-Based Screening and Assistance Program

Abstracts: Healthcare Disparities in Rheumatology

1:00PM-2:30PM: Abstract Number: 2540

Characterizing the Functional Role of Type I Interferons in Inflammatory Arthritis

Abstracts: RA – Animal Models

1:00PM-2:30PM: Abstract Number: 2561

Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women

Abstracts: Metabolic & Crystal Arthropathies

1:00PM-2:30PM: Abstract Number: 2570

Comparison of the Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis- Associated Lung Disease (SJIA-LD) Cohort to CARRA Registry SJIA Patients Without Lung Disease

Abstracts: Pediatric Rheumatology – Clinical I

1:00PM-2:30PM: Abstract Number: 2560

Continuous Reduction in Ultrasound Detected Crystal Depositions over 5 Years Follow-up: Results from the NOR-Gout Study

Abstracts: Metabolic & Crystal Arthropathies

1:00PM-2:30PM: Abstract Number: 2534

Deciphering Complement-dependent Macrophage Phenotypes in Human Rheumatoid Arthritis Using Combined Computational-experimental Single-cell Omics

Abstracts: Genetics, Genomics & Proteomics

1:00PM-2:30PM: Abstract Number: 2566

Detrimental Effects of Proton Pump Inhibitors on Bone Mineral Density Are Not Mediated by Changes in Serum Calcium or Parathyroid Hormone in Patients with Inflammatory Rheumatic Diseases: A Cross-sectional Study

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science

1:00PM-2:30PM: Abstract Number: 2558

Development of Non-genetic Risk Stratification Model of Severe Allopurinol Hypersensitivity Syndrome, a Multicenter Study in Thailand

Abstracts: Metabolic & Crystal Arthropathies

1:00PM-2:30PM: Abstract Number: 2577

Efficacy and Safety of ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: Results Through 104 Weeks in a Long-Term Extension Study

Abstracts: SLE – Treatment II: Non-Cellular Lupus Therapeutics

1:00PM-2:30PM: Abstract Number: 2573

Efficacy and Safety of Ixekizumab in Children with Active Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis (COSPIRIT-JIA): 16-week Results of a Multicentre, Randomised, Open-label Study

Abstracts: Pediatric Rheumatology – Clinical I

1:00PM-2:30PM: Abstract Number: 2582

Efficacy and Safety of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Patients with Active PsA: 24-Week Results from a Global, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Abstracts: SpA Including PsA – Treatment II

1:00PM-2:30PM: Abstract Number: 2562

Efficacy and Safety of Tocilizumab in the Treatment of Chronic Inflammatory Forms of CPPD: Retrospective Study of 55 Cases

Abstracts: Metabolic & Crystal Arthropathies

1:00PM-2:30PM: Abstract Number: 2563

Efficacy and Safety Results of CT-P41 (Proposed Denosumab Biosimilar) Compared to Reference Denosumab in Postmenopausal Women with Osteoporosis: 78-Week Results from Phase 3 Randomized Controlled Trial

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science

1:00PM-2:30PM: Abstract Number: 2588

Examining the Influence of Socioeconomic Status on Osteoarthritis Prevalence and Risk Factors Among New York Residents

Abstracts: ARP Interprofessional I: Epidemiology & Methods

1:00PM-2:30PM: Abstract Number: 2567

Gene Expression in Osteonecrosis of the Femoral Head: A Region-matched RNA-sequencing Study

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].